Table 1 Baseline demographic and clinical characteristics among rivaroxaban, dabigatran and warfarin groups
Baseline characteristics | Rivaroxaban (n = 362) | Dabigatran (n = 186) | Warfarin (n = 126) | P |
|---|---|---|---|---|
Age (y) | 69.69 ± 8.11 | 69.91 ± 8.22 | 68.45 ± 8.71 | 0.280 |
Gender (Male, %) | 57.7% | 64.5% | 59.5% | 0.307 |
Stroke and bleeding risk factors | ||||
 CHF | 1.1% | 1.6% | 2.4% | 0.517 |
 Hypertension | 61.6% | 57.5% | 55.6% | 0.413 |
 Age > 75y | 22.4% | 26.9% | 23.0% | 0.491 |
 Diabetes mellitus | 18.8% | 21.0% | 15.9% | 0.528 |
 Stroke/TIA | 45.9% | 45.7% | 42.9% | 0.665 |
 Vascular disease | 10.8% | 13.4% | 14.3% | 0.480 |
 Age (65–74y) | 53.6% | 43.5% | 48.4% | 0.079 |
 Sex category (female gender) | 42.3% | 35.5% | 40.5% | 0.307 |
 Abnormal renal function | 5.0% | 3.8% | 5.6% | 0.733 |
 Abnormal liver function | 2.2% | 2.2% | 3.2% | 0.789 |
 Bleeding history | 9.1% | 10.2% | 9.5% | 0.917 |
 Drug interactions | 37.3% | 36.6% | 46.0% | 0.172 |
 Alcohol | 7.2% | 11.8% | 7.1% | 0.152 |
Coronary heart disease | 17.1% | 16.7% | 14.3% | 0.757 |
Watchman Size (mm) | 27.11 ± 3.89 | 27.06 ± 3.93 | 27.31 ± 4.21 | 0.855 |
LVEF, % | 47.37 ± 6.25 | 46.75 ± 6.25 | 48.17 ± 8.03 | 0.256 |
CHA2DS2-VASc score | 3.08 ± 1.48 | 3.21 ± 1.57 | 3.17 ± 1.53 | 0.614 |
 3–4 | 45.9% | 45.7% | 46.0% | 0.998 |
 ≥5 | 16.6% | 21.0% | 21.4% | 0.313 |
HAS-BLED score | 3.60 ± 1.18 | 3.56 ± 1.19 | 3.65 ± 1.14 | 0.816 |
 0–2 | 21.0% | 20.4% | 17.5% | 0.692 |
 ≥3 | 79.0% | 79.6% | 82.5% | 0.692 |